Verastem (VSTM) Expected to Announce Quarterly Earnings on Thursday

Verastem (NASDAQ:VSTM - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $0.15 million for the quarter.

Verastem Trading Up 0.6 %

Shares of Verastem stock traded up $0.04 during trading hours on Friday, hitting $7.00. The company's stock had a trading volume of 1,264,513 shares, compared to its average volume of 1,155,643. Verastem has a 1-year low of $2.10 and a 1-year high of $13.52. The business has a fifty day moving average of $5.77 and a 200 day moving average of $4.31. The company has a market capitalization of $311.55 million, a PE ratio of -2.19 and a beta of 0.60. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77.

Insider Buying and Selling at Verastem

In other Verastem news, CEO Dan Paterson sold 8,568 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $5.24, for a total transaction of $44,896.32. Following the transaction, the chief executive officer now directly owns 347,581 shares in the company, valued at $1,821,324.44. This represents a 2.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 10,367 shares of company stock worth $53,990 in the last ninety days. 2.20% of the stock is owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

VSTM has been the subject of several recent research reports. Mizuho increased their price objective on shares of Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Thursday, December 19th. Guggenheim reissued a "buy" rating on shares of Verastem in a research report on Friday, January 24th. Royal Bank of Canada upped their target price on shares of Verastem from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, January 7th. StockNews.com downgraded shares of Verastem from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Finally, B. Riley upped their target price on shares of Verastem from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.63.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.